International Science Index


10008984

Identification of Promiscuous Epitopes for Cellular Immune Responses in the Major Antigenic Protein Rv3873 Encoded by Region of Difference 1 of Mycobacterium tuberculosis

Abstract:

Rv3873 is a relatively large size protein (371 amino acids in length) and its gene is located in the immunodominant genomic region of difference (RD)1 that is present in the genome of Mycobacterium tuberculosis but deleted from the genomes of all the vaccine strains of Bacillus Calmette Guerin (BCG) and most other mycobacteria. However, when tested for cellular immune responses using peripheral blood mononuclear cells from tuberculosis patients and BCG-vaccinated healthy subjects, this protein was found to be a major stimulator of cell mediated immune responses in both groups of subjects. In order to further identify the sequence of immunodominant epitopes and explore their Human Leukocyte Antigen (HLA)-restriction for epitope recognition, 24 peptides (25-mers overlapping with the neighboring peptides by 10 residues) covering the sequence of Rv3873 were synthesized chemically using fluorenylmethyloxycarbonyl chemistry and tested in cell mediated immune responses. The results of these experiments helped in the identification of an immunodominant peptide P9 that was recognized by people expressing varying HLA-DR types. Furthermore, it was also predicted to be a promiscuous binder with multiple epitopes for binding to HLA-DR, HLA-DP and HLA-DQ alleles of HLA-class II molecules that present antigens to T helper cells, and to HLA-class I molecules that present antigens to T cytotoxic cells. In addition, the evaluation of peptide P9 using an immunogenicity predictor server yielded a high score (0.94), which indicated a greater probability of this peptide to elicit a protective cellular immune response. In conclusion, P9, a peptide with multiple epitopes and ability to bind several HLA class I and class II molecules for presentation to cells of the cellular immune response, may be useful as a peptide-based vaccine against tuberculosis.

References:
[1] Daniel TM. 2006. The history of tuberculosis. Resp Med 100: 1862-1870
[2] WHO Report. 2017. Global tuberculosis report. http://www.who.int/tb/publications/global_report/en/
[3] Mustafa AS, Al-Attiyah R. 2003. Tuberculosis: Looking beyond BCG vaccines. J Postgrad Med 49:129-140.
[4] Mustafa AS. 2005. Progress towards the development of new anti-tuberculosis vaccines. In: Focus on Tuberculosis Research, Editor: Lucy T. Smithe, Nova Science Publishers, Inc., New York, pp. 47-76.
[5] Mustafa AS. 2012. What’s new in the development of tuberculosis vaccines. Med Princ Pract 21:195-196.
[6] Mustafa AS. 2018. Antigens for DNA vaccines against tuberculosis. Mycobact Dis 8:255. doi:0.4172/2161-1068.1000255.
[7] Mustafa AS. 2016. BCG pros and cons and new/improved vaccines for tuberculosis. In: Text Book of Biochemistry, Biotechnology, Allied and Molecular Medicine, Fourth Edition. Editors: Talwar GP, Hasnain SE, Sarin SK & Sayed Hasnain, Publisher: PHI Learning Private Limited, Delhi, India. Chapter 117, pp. 1347-1353.
[8] Nuttall JJ, Eley BS. 2011. BCG Vaccination in HIV-Infected Children. Tuberc Res Treat 2011:712736.
[9] Mustafa AS. 2009. Vaccine potential of Mycobacterium tuberculosis-specific genomic regions: in vitro studies in humans. Expert Rev Vaccines 8:1309-1312.
[10] Mustafa AS, Amoudy HA, Oftung F, Wiker HG, Abal AT, Ravn P, Andersen P. 1998. Comparison of antigen specific T cell responses of tuberculosis patients using complex or single antigens of Mycobacterium tuberculosis. Scand J Immunol 48:535 543.
[11] Al-Attiyah R, Mustafa AS, Abal AT, Madi NM, Andersen P. 2003. Restoration of mycobacterial antigen-induced proliferation and interferon-γ responses in peripheral blood mononuclear cells of tuberculosis patients upon effective chemotherapy FEMS Immunol Med Microbiol 38:249-256.
[12] Al-Attiyah R, Mustafa AS, Abal AT, El-Shamy AM, Dalemans W, Skeiky YAW. 2004. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin Exp Immunol 138:139-144.
[13] Al-Attiyah R, N Madi, AS El-Shamy, W Harald, P Andersen, Mustafa AS. 2006. Cytokine profiles in tuberculosis patients and healthy subjects in response to complex and single antigens of Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 47:254-461.
[14] Al-Attiyah R, Mustafa AS. 2008. Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG. Infect Immun 76:4190-4198.
[15] Mustafa AS, El-Shamy AM, Madi NM, Amoudy HA, Al-Attiyah R. 2008. Cell mediated immune responses to complex and single mycobacterial antigens in tuberculosis patients with diabetes. Med Princ Pract 17:325-330
[16] Mustafa AS, Al-Attiyah R. 2009. Identification of Mycobacterium tuberculosis-specific genomic regions encoding antigens those induce qualitatively opposing cellular immune responses. Ind J Exp Biol 47:498-504.
[17] Al-Attiyah R, Mustafa AS. 2010. Characterization of human cellular immune responses to Mycobacterium tuberculosis proteins encoded by genes predicted in RD15 genomic region that is absent in Mycobacterium bovis BCG. FEMS Immunol Med Microbiol 59:177-187.
[18] Mustafa AS, Al-Saidi F, El-Shamy ASM and Al-Attiyah R. 2011. Cytokines in response to proteins predicted in genomic regions of difference of Mycobacterium tuberculosis. Microbiol Immunol 55:267-278.
[19] Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. 2010. The immunology of tuberculosis: From bench to bedside. Respirology 15:433–450.
[20] Mustafa AS, Qvigstad E. 1989. HLA DR restricted antigen induced proliferation and cytotoxicity mediated by CD4+ T cell clones from subjects vaccinated with killed M. leprae. Int J Lepr Other Mycobact Dis 57: 1 11.
[21] Mustafa, AS, Lundin KEA, Oftung F. 1993. Human T cells recognize mycobacterial heat shock proteins in the context of multiple HLA DR molecules. Studies in healthy subjects vaccinated with Mycobacterium bovis BCG and Mycobacterium leprae. Infect Immun 61: 5294 5301.
[22] Oftung F, Geluk A, Lundin KEA, Meloen RH, Thole JER, Mustafa AS, Ottenhoff THM. 1994. Mapping of multiple HLA Class II restricted T cell epitopes of the mycobacterial 70 kDa heat shock protein. Infect Immun 62: 5411 5418.
[23] Mustafa AS, Deggerdal A, Lundin KEA, Meloen RM, Shinnick TM, Oftung F. 1994. An HLA-DRw53-restricted T-cell epitope from a novel Mycobacterium leprae protein antigen important to the human memory T-cell repertoire against M. leprae. Infect Immun 62: 5595 5602.
[24] Mustafa AS. 1995. Identification of mycobacterial peptide epitopes recognized by CD4+ T cells in association with multiple MHC class II molecules. Nutrition 11: 657 660.
[25] Mustafa AS, KEA Lundin, RM Meloen, TM Shinnick, AFW Coulson, F Oftung. 1996. HLA DR4 restricted T cell epitope from the mycobacterial 60 kDa heat shock protein (HSP60) do not map to the sequence homology regions with human HSP60. Immunology 87:421 427.
[26] Mustafa AS, Oftung F. 1996. Amino acid sequence and HLA-DR restriction of peptide defined T cell epitopes from somatic antigens of mycobacteria. Kuwait Med J (Supplementary Issue) 244 247.
[27] Mustafa AS, Nadeem S, Amoudy HA. 1996. Identification of HLA¬DR molecules frequently expressed by peripheral blood mononuclear cells of healthy subjects responding to mycobacterial antigens. Kuwait Med J (Supplementary Issue) 323 327.
[28] Oftung F, Lundin KEA, Geluk G, Shinnick TM, Meloen R, Mustafa AS. 1997. Primary structure and MHC restriction of peptide defined T cell epitopes from recombinantly expressed mycobacterial protein antigens. Med Princ Pract 6: 66 73.
[29] Mustafa AS, Shaban FA, Abal AT, Al Attiyah R, Wiker HG, Lundin KEA, Oftung F, Huygen K. 2000. Identification and HLA restriction of naturally derived Thl cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen specific human CD4+ T cell lines. Infect Immun 68:3933-3940.
[30] Mustafa AS, Lundin KEA, Meloen RH, Oftung F. 2000. Crossreactive epitopes and HLA restriction elements in human T cell recognition of the Mycobacterium leprae 18 kD heat shock protein. Clin Exp Immunol 120:85-92.
[31] Mustafa AS, Shaban FA, Al-Attiyah RJ, Abal AT, El-Shamy AM, Andersen P, Oftung F. 2003. Human Th1 cell lines recognize the Mycobacterium tuberculosis ESAT-6 antigen and its peptides in association with frequently expressed HLA class II molecules. Scand J Immunol 57:125-134.
[32] Al-Attiyah R, Mustafa AS. 2004. Computer-assisted prediction of HLA-DR binding and experimental analysis for human promiscuous Th1 cell peptides in a novel 24-kDa secreted lipoprotein (LppX) of Mycobacterium tuberculosis. Scand J Immunol 59:16-24.
[33] Mustafa AS, Abal AT, Shaban F, El-Shamy AM, Amoudy HA. 2005. HLA-DR binding prediction and experimental evaluation of mycolyltransferase (Ag85B), a major secreted antigen of Mycobacterium tuberculosis. Med Princ Pract 14:140-146.
[34] Mustafa AS. 2000. HLA restricted immune response to mycobacterial antigens: relevance to vaccine design. Hum Immunol 61:166-171.
[35] Mustafa AS, Al-Attiyah R. 2004. Mycobacterium tuberculosis antigens and peptides as new vaccine candidates and immunodiagnostic reagents against tuberculosis. Kuwait Med J 36: 171-176.
[36] Mustafa AS. 2005. Mycobacterial gene cloning and expression, comparative genomics, bioinformatics and proteomics in relation to the development of new vaccines and diagnostic reagents. Med Princ Pract 14 Suppl 1:27-34.
[37] Mustafa AS. 2010. Cell mediated immunity assays identify proteins of diagnostic and vaccine potential from genomic regions of difference of Mycobacterium tuberculosis. Kuwait Med J 42:98-105.
[38] Mustafa AS. 1997. Development of improved vaccines against tuberculosis. Med Princ Pract 6: 55.
[39] Mustafa AS. 2001. Biotechnology in the development of new vaccines and diagnostic reagents against tuberculosis. Curr Pharm Biotechnol 2: 157-173.
[40] Mustafa AS. 2012. What's New in the Development of Tuberculosis Vaccines. Med Princ Pract 21:195-196.
[41] Mustafa AS, Godal T. 1983. In vitro induction of human suppressor T cells by mycobacterial antigens. BCG activated OKT4 + T cells mediate suppression of antigen induced proliferation. Clin Exp Immunol 52: 29 37.
[42] Mustafa AS, Godal T. 1985. BCG induced suppressor T cells. Optimal conditions for in vitro induction and mode of action. Clin Exp Immunol 62: 474 481.
[43] Mustafa AS, Kvalheim G, Degre M, Godal T. 1986. Mycobacterium bovis BCG induced human T cell clones from BCG vaccinated healthy subjects: antigen specificity and lymphokine production. Infect Immun 53: 491 497.
[44] Mustafa AS. 2005. Recombinant and synthetic peptides to identify Mycobacterium tuberculosis antigens and epitopes of diagnostic and vaccine relevance. Tuberculosis (Edinb) 85:367-76.
[45] Mustafa AS, Shaban FA. 2006. ProPred analysis and experimental evaluation of promiscuous Th1 cell epitopes of three major secreted antigens of Mycobacterium tuberculosis. Tuberculosis (Edinb) 86:115-24.
[46] Hanif SNM, El-Shammy AM, Al-Attiyah R, Mustafa AS. 2008. Whole blood assays to identify Th1 cell antigens and peptides encoded by Mycobacterium tuberculosis-specific RD1 genes. Med Princ Pract 17:244-249.
[47] Mustafa AS. 2009. HLA-promiscuous Th1-cell reactivity of MPT64 (Rv1980c), a major secreted antigen of Mycobacterium tuberculosis, in healthy subjects. Med Princ Pract 18:385-392.
[48] Mustafa AS, Al-Attiyah R. 2009. Identification of Mycobacterium tuberculosis-specific genomic regions encoding antigens those induce qualitatively opposing cellular immune responses. Ind J Exp Biol 47:498-504.
[49] Mustafa AS. 2009. Th1-cell reactivity and HLA-DR binding prediction for promiscuous recognition of MPT63 (Rv1926c), a major secreted protein of Mycobacterium tuberculosis. Scand J Immunol 69:213-222.
[50] Al-Attiyah R, Mustafa AS. 2010. Characterization of human cellular immune responses to Mycobacterium tuberculosis proteins encoded by genes predicted in RD15 genomic region that is absent in Mycobacterium bovis BCG. FEMS Immunol Med Microbiol 59:177-187.
[51] Mustafa AS. 2011. Comparative evaluation of MPT83 (Rv2873) for T helper-1 cell reactivity and identification of HLA-promiscuous peptides: studies in M. bovis BCG-vaccinated healthy subjects. Clin Vaccine Immunol 18: 1752-1759.
[52] Mustafa AS. 2010. In silico binding predictions for identification of HLA-DR-promiscuous regions and epitopes of Mycobacterium tuberculosis protein MPT64 (Rv1980c), and their recognition by human Th1 cells. Med Princ Pract 19:367-372.
[53] Shaban K, Amoudy HA, Mustafa AS. 2013. Cellular immune responses to recombinant Mycobacterium bovis BCG constructs expressing major antigens of region of difference 1 of Mycobacterium tuberculosis. Clin Vaccine Immunol 20:1230-1237.
[54] Amoudy HA, Ebrahimi BH, Mustafa AS. 2014. Immune responses against Mycobacterium tuberculosis-specific proteins PE35 and CFP10 in mice immunized with recombinant Mycobacterium vaccae. Saudi Med J 35:350-359.
[55] Hanif SNM, Al-Attiyah R and Mustafa AS. 2010. Molecular cloning, expression, purification and immunological characterization of three low molecular weight proteins encoded by genes in genomic regions of difference of Mycobacterium tuberculosis. Scand J Immunol 71:353-361.
[56] Hanif SN, Al-Attiyah R, Mustafa AS. 2011. Cellular immune responses in mice induced by M. tuberculosis PE35-DNA vaccine construct. Scand J Immunol 74:554-60.
[57] Al-Attiyah R, El-Shazly A, Mustafa AS. 2012. Comparative analysis of spontaneous and mycobacterial antigen-induced secretion of Th1, Th2 and pro-inflammatory cytokines by peripheral blood mononuclear cells of tuberculosis patients. Scand J Immunol 75:623-632.
[58] Mustafa AS. 2014. T-helper 1, T-helper 2, pro-inflammatory and anti-inflammatory cytokines in tuberculosis. IJMPBS 3: 1-14.
[59] Mustafa AS. 2016. Immune responses to candidate vaccine antigens delivered through naked plasmid and mycobacterial vectors. Open Conf Proc J 7:153-199.
[60] Mustafa AS, Al-Attiyah R, Hanif SNM, Shaban FA. 2008. Efficient testing of pools of large numbers of peptides covering 12 open reading frames of M. tuberculosis RD1 and identification of major antigens and immunodominant peptides recognized by humanTh1 cells. Clin Vaccine Immunol 15:916-924.
[61] Mustafa AS. 2014. Characterization of a cross-reactive, immunodominant and HLA-promiscuous epitope of Mycobacterium tuberculosis-specific major antigenic protein PPE68. PLoS One 9:e103679.
[62] Singh H, Raghava GPS. 2001. ProPred: Prediction of HLA-DR binding sites. Bioinformatics 17: 1236-1237.
[63] Nielsen M, Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 2009; 10:296.
[64]
[http://www.imtech.res.in/raghava/mhc2pred.
[65] Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. 2017. NetMHCpan-4.0: Improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity. J Immunol 199:3360-3368.
[66] Calis JJ, Maybeno M, Greenbaum JA, Weiskopf D, De Silva AD, Sette A, Kesmir C, Peters B. 2013. Properties of MHC class I presented peptides that enhance immunogenicity. PloS Comp. Biol. 8:361.